THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Alnylam succeeds in sickening subjects so it can test drug

By Stephen Heuser
Globe Staff / July 27, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

The Cambridge biotechnology company Alnylam Pharmaceuticals Inc. made a big splash this month by inking one of the largest-ever deals in its industry, a partnership with drug giant Roche that could eventually be worth $1 billion. (Full article: 655 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass